-
Mashup Score: 0
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma.
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide plus low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [Oct 22, 2009] @VincentRK @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm